Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer

<p>Recurrence per PDL1 and MPR</p>

Guardado en:

Detalles Bibliográficos
Autor principal:	Samuel Rosner (15054884) (author)
Otros Autores:	Joshua E. Reuss (15054887) (author), Marianna Zahurak (15054890) (author), Jiajia Zhang (15054893) (author), Zhen Zeng (15054896) (author), Janis Taube (15054899) (author), Valsamo Anagnostou (14961731) (author), Kellie N. Smith (15054902) (author), Joanne Riemer (15054905) (author), Peter B. Illei (15054908) (author), Stephen R. Broderick (15054911) (author), David R. Jones (15044613) (author), Suzanne L. Topalian (15031475) (author), Drew M. Pardoll (14953549) (author), Julie R. Brahmer (15054914) (author), Jamie E. Chaft (14937195) (author), Patrick M. Forde (15054917) (author)
Publicado:	2025
Materias:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunotherapy Checkpoint blockade Lung Cancer
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares